Wanbury has successfully completed US Food and Drug Administration (USFDA) inspection a at its API facility in Patalganga Plant, Maharashtra. The audit was carried out for a period of 4 days from September 26 to September 29, 2016 and concluded successfully. This is the second plant to be approved by USFDA this year, as earlier Tanuku Plant got approval two months ago in July 2016.
Wanbury, one of India’s fastest growing pharmaceutical companies amongst the ‘Top 50 Companies’ in India (as per ORG-IMS), has a strong presence in API global market and domestic branded Formulation. The company’s major thrust area lies in Active Pharmaceutical Ingredient (API) sale in over 70 countries and Pan-India Formulation presence.
Mr. K. Chandran, Wholetime Director & Vice Chairman
MR K. CHANDRAN (left), Director, Wanbury, and Mr Asok Shinkar
//////////Wanbury, USFDA inspection, API facility, Patalganga Plant